Prelude Therapeutics Incorporated (NASDAQ:PRLD) insider David J. Mauro sold 15,000 shares of the firm’s stock in a transaction on Monday, June 7th. The shares were sold at an average price of $32.44, for a total transaction of $486,600.00. Following the sale, the insider now owns 15,000 shares in the company, valued at $486,600. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NASDAQ:PRLD opened at $32.04 on Friday. Prelude Therapeutics Incorporated has a 52 week low of $23.69 and a 52 week high of $95.38. The stock has a market cap of $1.50 billion and a PE ratio of -7.03. The business has a fifty day simple moving average of $36.63.
Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings data on Tuesday, March 16th. The company reported ($0.45) EPS for the quarter. Analysts forecast that Prelude Therapeutics Incorporated will post -2.12 earnings per share for the current year.
Several large investors have recently modified their holdings of PRLD. Strs Ohio purchased a new position in shares of Prelude Therapeutics in the 4th quarter worth $157,000. BlackRock Inc. lifted its holdings in shares of Prelude Therapeutics by 920.2% in the 4th quarter. BlackRock Inc. now owns 637,133 shares of the company’s stock worth $45,587,000 after acquiring an additional 574,683 shares during the last quarter. New York State Common Retirement Fund bought a new stake in shares of Prelude Therapeutics in the 4th quarter worth about $515,000. Alliancebernstein L.P. bought a new stake in shares of Prelude Therapeutics in the 4th quarter worth about $615,000. Finally, Personal CFO Solutions LLC bought a new stake in shares of Prelude Therapeutics in the 4th quarter worth about $322,000. 91.62% of the stock is owned by institutional investors and hedge funds.
Prelude Therapeutics Company Profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas.
Further Reading: How to invest in blue-chip stocks
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.